{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T06:57:17Z","timestamp":1777100237340,"version":"3.51.4"},"reference-count":41,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Micafungin is widely used for invasive candidiasis, especially in critically ill patients and those with cancer, and for empirical antifungal therapy in patients with neutropenic fever. This is the first study to investigate the pharmacokinetics and disposition parameters of micafungin in patients with cancer. In this observational pharmacokinetic study, blood samples were collected and analyzed using high-performance liquid chromatography. Pharmacokinetic parameters were estimated using Monolix 4.4 software. The plasma micafungin concentrations were measured in a total of 133 samples from 19 patients. In the final two-compartment model with linear elimination, the estimated micafungin clearance (CL) was significantly higher in patients with cancer than in those without cancer (1.2 vs. 0.6 L\/h, p = 0.012), whereas other parameters did not significantly differ between the two groups. Aspartate and alanine transaminases and body weight significantly influenced micafungin CL in patients, with and without cancer. Overall, the probability of target attainment increased with increasing doses and decreased with higher MICs in both groups. In simulations, the patients without cancer achieved higher pharmacokinetic\/pharmacodynamic targets with a 90% probability for all simulated doses, compared to the patients with cancer. Micafungin demonstrated dose-proportional linear pharmacokinetics in both the patients with and those without cancer. The estimated micafungin CL was significantly higher in patients with cancer, suggesting a need for increased dosage, especially for Candida spp. with high MICs, in these patients. Further studies should assess the efficacy and optimum dosage of micafungin for the treatment and prevention of febrile neutropenia (FN) in patients with cancer.<\/jats:p>","DOI":"10.3390\/antibiotics10111363","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T08:05:16Z","timestamp":1636358716000},"page":"1363","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Assessment of Micafungin Dosage Regimens in Patients with Cancer Using Pharmacokinetic\/Pharmacodynamic Modeling and Monte Carlo Simulation"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3839-8187","authenticated-orcid":false,"given":"Saeed","family":"Alqahtani","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia"},{"name":"Clinical Pharmacokinetics and Pharmacodynamics Unit, King Saud University Medical City, Riyadh 11451, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma","family":"Alfarhan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia"},{"name":"Clinical Pharmacokinetics and Pharmacodynamics Unit, King Saud University Medical City, Riyadh 11451, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7013-8369","authenticated-orcid":false,"given":"Abdullah","family":"Alsultan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia"},{"name":"Clinical Pharmacokinetics and Pharmacodynamics Unit, King Saud University Medical City, Riyadh 11451, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emad","family":"Alsarhani","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia"},{"name":"Clinical Pharmacokinetics and Pharmacodynamics Unit, King Saud University Medical City, Riyadh 11451, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1785-7214","authenticated-orcid":false,"given":"Abdulaziz","family":"Alsubaie","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia"},{"name":"Clinical Pharmacokinetics and Pharmacodynamics Unit, King Saud University Medical City, Riyadh 11451, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7046-5071","authenticated-orcid":false,"given":"Yousif","family":"Asiri","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","article-title":"Chemotherapy-induced neutropenia: Risks, consequences, and new directions for its management","volume":"100","author":"Crawford","year":"2004","journal-title":"Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00002820-200505000-00001","article-title":"Quality of life and chemotherapy-induced neutropenia","volume":"28","author":"Padilla","year":"2005","journal-title":"Cancer Nurs."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1093\/annonc\/mdr520","article-title":"Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre","volume":"23","author":"Schelenz","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/cam4.200","article-title":"Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: A nationwide prospective cohort study","volume":"3","author":"Culakova","year":"2014","journal-title":"Cancer Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1200\/JCO.2012.45.8661","article-title":"Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline","volume":"31","author":"Flowers","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jiph.2018.12.006","article-title":"Epidemiology and source of infection in patients with febrile neutropenia: A ten-year longitudinal study","volume":"12","author":"Hinedi","year":"2019","journal-title":"J. Infect. Public Health"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.7314\/APJCP.2013.14.2.1115","article-title":"Mortality, length of stay, and cost associated with hospitalized adult cancer patients with febrile neutropenia","volume":"14","author":"Chindaprasirt","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S331","DOI":"10.1093\/cid\/ciu598","article-title":"Invasive gram-positive bacterial infection in cancer patients","volume":"59","author":"Holland","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1086\/374339","article-title":"Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States","volume":"36","author":"Wisplinghoff","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/cid\/civ293","article-title":"Epidemiology and outcome of fungemia in a cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031)","volume":"61","author":"Cornely","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1002\/cncr.23466","article-title":"The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy","volume":"112","author":"Hachem","year":"2008","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO Clinical Practice Guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","article-title":"Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/CE.S36304","article-title":"Micafungin: An evidence-based review of its place in therapy","volume":"9","author":"Reboli","year":"2014","journal-title":"Core Evid."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/2047-783X-16-4-159","article-title":"Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: Review of the literature","volume":"16","author":"Kofla","year":"2011","journal-title":"Eur. J. Med. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/tcrm.2007.3.1.71","article-title":"Comparison of echinocandin antifungals","volume":"3","author":"Eschenauer","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s10096-004-1228-z","article-title":"Pharmacokinetics\/pharmacodynamics of echinocandins","volume":"23","author":"Theuretzbacher","year":"2004","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40262-017-0578-5","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Micafungin","volume":"57","author":"Wasmann","year":"2018","journal-title":"Clin. Pharmacokinet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/17425255.2016.1179281","article-title":"Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol","volume":"12","author":"Franken","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1093\/jac\/dkv173","article-title":"Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis","volume":"70","author":"Grau","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/jac\/dkw352","article-title":"Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation","volume":"72","author":"Jullien","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s40262-017-0509-5","article-title":"Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients","volume":"56","author":"Martial","year":"2017","journal-title":"Clin. Pharmacokinet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1128\/AAC.01647-09","article-title":"Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients","volume":"54","author":"Walsh","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.jchromb.2011.05.033","article-title":"Determination of micafungin and anidulafungin in human plasma: UV- or mass spectrometric quantification?","volume":"879","author":"Rupprecht","year":"2011","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10928-006-9043-z","article-title":"Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software","volume":"34","author":"Lavielle","year":"2007","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e00088-18","DOI":"10.1128\/AAC.00088-18","article-title":"Population Pharmacokinetic Model for Vancomycin Used in Open Heart Surgery: Model-Based Evaluation of Standard Dosing Regimens","volume":"62","author":"Alqahtani","year":"2018","journal-title":"Antimicrob. Agents Chemother"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e02241-17","DOI":"10.1128\/AAC.02241-17","article-title":"Population Pharmacokinetic Model-Based Evaluation of Standard Dosing Regimens for Cefuroxime Used in Coronary Artery Bypass Graft Surgery with Cardiopulmonary Bypass","volume":"62","author":"Alqahtani","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO.2000.18.6.1337","article-title":"Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study","volume":"18","author":"Findlay","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.01430-10","article-title":"Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia","volume":"55","author":"Andes","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1128\/AAC.35.7.1501","article-title":"Gentamicin pharmacokinetics in patients with malignancies","volume":"35","author":"Bertino","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00228-019-02657-6","article-title":"The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults","volume":"75","author":"Bury","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/44.2.235","article-title":"Population pharmacokinetics of amikacin in patients with haematological malignancies","volume":"44","author":"Romano","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.diagmicrobio.2007.09.018","article-title":"Population pharmacokinetics of micafungin in adult patients","volume":"60","author":"Gumbo","year":"2008","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1128\/AAC.05193-11","article-title":"Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people","volume":"55","author":"Hall","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13054-018-2019-8","article-title":"Population pharmacokinetics\/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients","volume":"22","author":"Maseda","year":"2018","journal-title":"Crit. Care"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"324","DOI":"10.2133\/dmpk.21.324","article-title":"Population pharmacokinetic analysis of micafungin in Japanese patients with fungal infections","volume":"21","author":"Tabata","year":"2006","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1093\/jac\/dkr323","article-title":"Micafungin therapy in a critically ill, morbidly obese patient","volume":"66","author":"Zomp","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_40","first-page":"1457","article-title":"Changes in hepatic parenchymal blood flow with colorectal metastases: Increase in arterial and decrease in portal blood flow","volume":"50","author":"Kunishima","year":"2003","journal-title":"Hepatogastroenterology"},{"key":"ref_41","first-page":"3267","article-title":"Hepatic blood flow by perfusion computed tomography as an imaging biomarker for patients with gastric cancer","volume":"17","author":"Shuto","year":"2019","journal-title":"Oncol. Lett."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/11\/1363\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:27:21Z","timestamp":1760167641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/11\/1363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["antibiotics10111363"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10111363","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,8]]}}}